Built from Insight Molecular Diagnostics Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
IMDX · Nasdaq · Healthcare · Diagnostics and Research
$2.41-2.4%Nov 11 close
Next earnings: November 16, 2026 · after the close
Figures through June 30, 2026, from the 10-Q filed August 10, 2026
The themes Insight Molecular Diagnostics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
TMOThermo Fisher Scientific Inc.$265.9BA+
IDXXIdexx Laboratories Inc.$55.4BA+
IQVIQVIA Holdings Inc.$45.2BA
ILMNIllumina, Inc.$32.2BA+
LHLabcorp Holdings Inc.$30.2BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now A
EWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now A
BIIBBiogen Inc.Oct 28, 2026BAGraded B, now AGrade F
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 26 quarters of Insight Molecular Diagnostics Inc.’s grade history. The other 24 go back to February 2017.